Stock of the Day

December 27, 2021

Halozyme Therapeutics (HALO)

$77.81
+$0.27 (+0.3%)
Market Cap: $9.20B

About Halozyme Therapeutics

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

Today's Trend

Halozyme Therapeutics, Inc. (NASDAQ:HALO) is getting a lift today after a wave of analyst estimate revisions and upbeat commentary pointed to stronger earnings ahead. Zacks Research raised its forecasts for several future periods, including FY2026, FY2027, and FY2028, which suggests improving profit expectations and supports the stock’s valuation. The stock is also drawing attention because recent insider sales by CEO Helen Torley were disclosed, though those trades were made under pre-arranged 10b5-1 plans and are generally seen as less concerning than discretionary selling.

  • Zacks Research raised Halozyme’s earnings estimates across multiple future periods, including FY2026, FY2027, and FY2028, signaling confidence in the company’s longer-term profit growth. Halozyme Therapeutics article
  • Analysts also increased estimates for several individual quarters in 2027, reinforcing a constructive earnings outlook for Halozyme Therapeutics. Halozyme Therapeutics article
  • One near-term forecast was trimmed slightly and another was revised lower, but the overall analyst tone remains mostly favorable. Halozyme Therapeutics article
  • Recent insider selling by the CEO was disclosed, but the trades were executed under a pre-arranged trading plan, which typically lessens investor concern. Halozyme Therapeutics article

Overall, HALO appears to be trading higher because investors are focusing more on the upgraded earnings outlook than on the insider sales.

← Previous Stock of the DayNext Stock of the Day →

Recent News